Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Five Charged in U.S. with Stealing Secrets from GlaxoSmithKline

Bill Berkrot  |  January 23, 2016

REUTERS—Five people, including two former GlaxoSmithKline researchers, were charged with a scheme to steal trade secrets from the British drugmaker for potential sale in China, according to indictments announced by the U.S. Attorney’s Office in Philadelphia on Wednesday.

The indictments include charges of conspiracy to steal trade secrets, conspiracy to commit wire fraud, conspiracy to commit money laundering, theft of trade secrets and wire fraud.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The stolen information on drugs for cancer and other serious diseases “potentially could be sold for millions of dollars to rival pharmaceutical companies and it would also be useful information for a start-up pharmaceutical company,” the complaint said.

The alleged conspirators established three corporations, one incorporated in Delaware and two likely in China, all using the name Renopharma, to sell the stolen information that could be used to reproduce Glaxo products and drugs in development, to competitors in China, according to the complaint.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One of the five, Yu Xue, was a senior-level manager and biotechnology expert at a Glaxo research facility in Pennsylvania with access to a wide array of secret information. She was fired Jan. 6, 2016, Glaxo said.

She is accused of sending confidential information related to a dozen or more products to fellow “conspirators and others,” and also downloading a substantial amount of Glaxo intellectual property to pass along as part of the alleged scheme.

A motion aimed at keeping Yu Xue detained that was filed earlier this month said she “stole millions, perhaps billions, of dollars’ worth of trade secret and other confidential information from her employer, GlaxoSmithKline, to resell in China.”

“Ms. Xue denies these allegations. She has pled not guilty and intends to contest these charges vigorously in court,” her attorney Peter Zeidenberg of Arent Fox said in an emailed statement.

The others named were Lucy Xi, a Glaxo scientist who left the company in November 2015, Tao Li, Yan Mei and Tian Xue, who is Yu Xue’s twin sister. The sister was used to hide proceeds of the crime, according to the complaint.

Mei is still being sought by authorities. Tao Li remains in custody, while the other three were arrested and released on bail, a spokeswoman for the U.S. Attorney’s office said.

Glaxo said it has been cooperating with authorities. “We do not believe the breach has had any material impact on the company’s business or R&D activity,” it said in a statement.

The alleged crimes took place between Jan. 1, 2012 and Dec. 28, 2015, the complaint said.

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:ChinaDrugsGlaxoSmithKlineInternationalLegal

Related Articles

    Moonshot: Apollo 11, Vaccines & Other Conspiracies

    September 14, 2021

    On July 20, 1969, at 10:56 p.m. EDT, American astronaut Neil Armstrong stepped off the lunar landing module, Eagle, and walked on the moon.1 Or so they would have you believe. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEFor most, the basic facts are not in dispute: On May 25, 1961, President John F. Kennedy delivered a speech…

    Rheumatology in China from Its Beginning to Today

    October 18, 2018

    Rheumatology in China is a relatively young discipline, but it has developed exponentially over the past three decades. In this article, we review the history of rheumatology in China and advances in clinical care, research and education in this field. The Founding Father Naizheng Zhang, MD, is widely regarded as the father of rheumatology in…

    Five Charged in $600 million California Healthcare Fraud Scheme

    November 29, 2015

    LOS ANGELES (Reuters)—The former chief financial officer of a California hospital and four other people have been charged in a series of health care kickback schemes that generated nearly $600 million in fraudulent billings for spinal surgeries, prosecutors said on Tuesday. All five defendants have agreed to cooperate in a wide-ranging federal investigation into the…

    Stealing Time

    September 17, 2019

    I knew I shouldn’t look. I was driving 60 miles per hour, heading north on I-95, trying to get to the George Washington Bridge before dusk. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEIt takes a certain fatalism to drive through New York City if you are not a native. Ninety percent of the drivers sharing the road…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences